A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bayer
Study ID
NCT07330258
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Standard of Care — OTHER
    Follow clinical practice/administration. No investigational products will be administered in this study. Patients will be treated in accordance with standard of care as determined by their clinician.

Study Details

This is an observational study in which data are collected and studied from Parkinson's disease patients who have movement symptoms despite taking standard Parkinson's medications. In observational studies, observations are made without any changes to the participant's healthcare or treatment plan. No investigational product will be administered in this study, as participants will be treated with the standard of care that medical experts currently consider most appropriate. Parkinson's disease (PD) is a condition that affects the brain and causes problems with movement and other body functions. The symptoms of Parkinson's disease can worsen over time. People with Parkinson's disease may experience shaking (tremor), slow movements, stiff muscles, trouble walking, and problems with balance. They can also have other symptoms, such as difficulty thinking clearly, changes in mood, or difficulty sleeping. Parkinson's disease mostly affects older adults, but it can happen to younger people too. There is no cure, but treatments can help manage the symptoms and improve quality of life. While doctors and researchers know that Parkinson's disease affects people in different ways and can worsen over time, there are still many things they don't fully understand-especially for people who experience movement symptoms despite taking their usual Parkinson's medicines. Earlier studies did not follow these patients long enough or collect all the important information needed. This study is being done to fill those gaps. The main purpose of this study is to better understand how Parkinson's disease changes over time in patients who experience movement symptoms while taking standard oral Parkinson's medications, what challenges patients and their care partners face, and how their treatments are working in real life. To do this, researchers will collect data on: * Sociodemographics (e.g. age, gender, race/ethnicity, insurance provider). * Medical history and vital signs (e.g. comorbidities, family history of Parkinson's, height, weight, blood pressure). * Medications and treatments (e.g. Parkinson's and non-Parkinson's medications and other treatments, rehabilitation therapy sessions, use of mobility assistance devices). * Movement symptoms (e.g. tremor, slow movement, balance). * Non-movement symptoms (e.g. cognition, mood, sleep, activities of daily living). * Molecular data (e.g. genetics, α-synuclein). * Burden of care (e.g. economic cost). Data will come from questionnaires or rating scales conducted by the doctor with the patient during study visits, diaries and logs completed by the patient, medical records, health insurance claims records, blood samples and skin biopsies, a digital device that records movement/non-movement symptoms, and questionnaires completed by the care partner. Data will be collected from December 2025 to December 2032. Each participant may be followed for up to 5 years.

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Dec 21, 2032
Completion
Jun 1, 2033

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Parkinson's Disease Cohort
    A single cohort of patients with Parkinson's disease experiencing motor complications while receiving standard-of-care oral therapies. The care partner of the patient may also participate in the study.
  • Arm: Care Partners Cohort
    The care partner of the patient may also participate in the study.

Primary Outcome Measure

Descriptive summary of motor outcomes among Parkinson's disease patients treated with oral antiparkinsonian medications who experience motor complications. [ Time Frame: From baseline up to 5 years ]

Central Contacts

Locations (26)

FacilityCityStateZIPSite coordinators
Banner Alzheimer's Institute (BAI)-PhoenixPhoenixArizona85006-
University of Arizona Banner Alzheimer's Institute (BAI)-TucsonTucsonArizona85721-
The Parkinson's & Movement Disorder InstituteFountain ValleyCalifornia92708-
Keck School of MedicineLos AngelesCalifornia90033-
Baptist Health Miami Neuroscience InstituteMiamiFlorida33176-
AdventHealth Neuroscience InstituteOrlandoFlorida32804-
University of South FloridaTampaFlorida33612-
Morehouse HealthcareAtlantaGeorgia30310-
Medical College of Georgia at Augusta UniversityAugustaGeorgia30912-
Northwestern Memorial HealthCare at Central DuPage HospitalWinfieldIllinois60190-
MedStar Montgomery Medical CenterOlneyMaryland20832-
Boston Medical CenterBostonMassachusetts02215-
University of MichiganAnn ArborMichigan48109-
Rutgers - Robert Wood Johnson Medical SchoolNew BrunswickNew Jersey08901-
Northwell HealthNew YorkNew York10016-
Stony Brook UniversityStony BrookNew York11794-
University of BuffaloWilliamsvilleNew York14221-
Cleveland ClinicClevelandOhio44195-
Thomas Jefferson UniversityPhiladelphiaPennsylvania19107-
Baylor College of MedicineHoustonTexas77030-
University of Texas Health Science Center at HoustonHoustonTexas77030-
Intermountain HealthMurrayUtah84107-
University of VermontBurlingtonVermont05402-
University of VirginiaCharlottesvilleVirginia22903-
Sentara Neurology SpecialistsNorfolkVirginia23510-
VA Puget Sound Health Care SystemSeattleWashington98108-

Find similar trials in Phoenix, AZ

Related Studies